Search

Your search keyword '"Miura, Satoru"' showing total 29 results

Search Constraints

Start Over You searched for: Author "Miura, Satoru" Remove constraint Author: "Miura, Satoru" Publisher springer science and business media llc Remove constraint Publisher: springer science and business media llc
29 results on '"Miura, Satoru"'

Search Results

1. Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)

2. Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

3. Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)

4. Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer

5. Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial

8. Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC

9. A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)

10. Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study

11. A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol

12. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

13. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

14. A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016)

15. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors

16. The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients

20. DEAD/H (Asp–Glu–Ala–Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells

21. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy

25. 18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors

29. Abstracts of selected papers presented at the 33rd annual meeting of the japanese society of gastroenterology

Catalog

Books, media, physical & digital resources